Lymphoma News

The FDA announced several regulatory actions.

Results from the American Association for Cancer Research’s annual Cancer Progress Report revealed that the age-adjusted overall cancer death rate in the U.S. fell by 33% between 1991 and 2020.

The addition of metformin to standard chemotherapy improved outcomes for patients with diffuse large B-cell lymphoma, according to findings presented at Society of Hematologic Oncology Annual Meeting.

An infusion of lisocabtagene maraleucel induced deep and durable responses among most adults with relapsed or refractory follicular lymphoma, according to results of the phase 2 TRANSCEND FL trial.

Several factors contributed to inequities of outcomes among people with hematologic malignancies in the United States, according to findings presented at Society of Hematologic Oncology Annual Meeting.

Patients with cancer experienced a greater burden of COVID-19-associated mortality during the winter Omicron wave than the general U.S. population, according to study results published in JAMA Oncology.

Now that chimeric antigen receptor T-cell therapy has become part of the treatment landscape in hematologic malignancies, researchers are focused on developing more potent, less toxic agents that can be used in earlier treatment settings.

CHICAGO — Epcoritamab plus R-CHOP induced high complete metabolic response rates in previously untreated high-risk diffuse large B-cell lymphoma and double-hit or triple-hit lymphoma, according to research presented at ASCO Annual Meeting.

CHICAGO — Loncastuximab tesirine and polatuzumab vedotin may show improved efficacy and manageable toxicity in patients with relapsed/refractory B-cell non-Hodgkin lymphoma, according to research presented at ASCO Annual Meeting.

An investigational chimeric antigen receptor T-cell therapy induced responses among patients with indolent lymphomas, according to topline data released by the agent’s manufacturer.